Your session is about to expire
← Back to Search
Virus Therapy
Avaxim Pediatric® for Autoimmune Rheumatic Disease
N/A
Waitlist Available
Led By Heinrike Schmeling, MD
Research Sponsored by University of Calgary
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Written informed consent provided for the subject by a parent or legal guardian.
Written informed assent from the participants themselves.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 to 7 months
Awards & highlights
Study Summary
This trial is comparing the immune response in immunosuppressed pediatric rheumatology patients to two different doses of Hepatitis A vaccine.
Eligible Conditions
- Autoimmune Rheumatic Disease
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 6 to 7 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 to 7 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Hepatitis A antibodies titre
Trial Design
2Treatment groups
Active Control
Group I: Avaxim Pediatric®Active Control1 Intervention
2 doses (0.5 mL each) six months apart of Avaxim Pediatric®
Group II: Avaxim ® (adult)Active Control1 Intervention
2 doses (0.5 mL each) six months apart of Avaxim ® (adult)
Find a Location
Who is running the clinical trial?
University of CalgaryLead Sponsor
780 Previous Clinical Trials
841,709 Total Patients Enrolled
Heinrike Schmeling, MDPrincipal InvestigatorUniversity of Calgary
1 Previous Clinical Trials
1,238 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Share this study with friends
Copy Link
Messenger